Biosimilars marketed in the US typically have list prices 15% to 35% lower than ... if needed – at mealtimes for example – with fast-acting insulins. The cost of insulin products has become ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls the new drug “Merilog,” a biosimilar to the widely-used insulin ...